|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||149.19 - 155.92|
|52 Week Range||71.46 - 167.86|
|PE Ratio (TTM)||216.85|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Vertex Pharmaceuticals Inc NASDAQ/NGS:VRTX
Gilead Sciences (GILD) has gained 13% during the past three months as investors have started to bet that the beaten-down biotech stock has finally found a bottom. The iShares Nasdaq Biotechnology ETF (IBB) has dipped 0.1% to $303.67.
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has turned in triple-digit gains so far this year after news that the firm is on the verge of having several new cystic fibrosis treatments FDA approved. At $149.38 per share, VRTX stock is expensive, but the question is whether or not the stock is too expensive. Have we already missed the boat or does the pharmaceutical company really have the growth potential that investors believe it does.